Mast cell activation syndrome (MCAS) affects more than 15% of the U.S. population but evades most practitioners’ radar. Just five years ago, it wasn’t even on my radar, despite already having 20 years of experience as a clinician at that time. The more I dug (similar to leaky gut and post-COVID syndrome), the more I found my patients were suffering from this disorder.
Sara Arscott, PhD, CCRP
Sara Arscott, PhD, CCRP, is the manager of clinical research at Standard Process Inc. In this role, she designs and prepares clinical research protocols and conducts, coordinates and monitors clinical trials. Arscott earned her doctorate in nutritional sciences from the University of Wisconsin-Madison in 2009. She can be reached at sarscott@standardprocess.com.